Coronaviridae is a family of enveloped RNA viruses known as Coronaviruses (CoVs) that provoke infections in animals and humans [
1,
2,
3,
4,
5,
6]. Presently, seven human coronaviruses (HCoVs), commonly considered of zoonotic origin, are described in the scientific literature [
7] that cause infections mainly associated with respiratory symptoms [
8,
9,
10]. More in detail, HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1 are “common cold” coronaviruses causing seasonal, usually mild, respiratory diseases [
11,
12]. Although, in most cases, these HCoVs do not lead to severe clinical symptoms, HCoV-NL63 and HCoV-HKU1 infections can provoke bronchiolitis and croup [
13,
14], whilst CoV 229E and OC43 can provoke pneumonia [
15,
16]. Nonetheless, three highly pathogenic HCoVs have emerged in the last two decades, i.e., Middle East Respiratory Syndrome (MERS)-CoV, Severe Acute Respiratory Syndrome (SARS)-CoV-1, and SARS-CoV-2 [
17,
18,
19], which can lead to life-threatening pathologic events associated with the recent MERS, SARS, and the current COronaVIrus Disease 19 (COVID-19), which is causing enormous problems globally in both sanitary and socioeconomic terms [
20]. SARS-CoV-1 and MERS-CoV are more lethal than SARS-CoV-2, but this latter is more transmissible, explaining the current pandemic status of COVID-19 [
21]. In the first step of coronavirus infection, a specific molecular recognition between the virus particle, through the virus spike (S) protein, and the host cell takes place, involving different HCoV-specific receptors [
22,
23,
24,
25,
26] that were identified for several CoVs and are considered one of the primary targets for anti-CoV biomedical strategies together with the SARS-CoV-2 main protease (M
pro) [
27,
28]. The receptors for the “common cold” HCoVs are human aminopeptidase N (APN), associated with the infection from HCoV-229E, and 9-O-acetylated sialic acid (9-O-Ac-Sia), used by HCoV-OC43 and HCoV-HKU1. On the other hand, the receptor for HCoV-NL63, i.e., angiotensin-converting enzyme 2 (ACE2), is also common to the more pathogenic SARS-CoV-1 and SARS-CoV-2, whilst dipeptidyl peptidase 4 (DPP4) was associated with MERS-CoV [
29,
30]. Once intracellular, all HCoVs replicate their RNA with the consequent expression of the viral proteins needed for the production of new viral particles inside the infected cell [
31]. As anticipated, four out of the seven HCoVs are associated with usually mild upper respiratory infections, whilst MERS-CoV and SARS-CoV-1 and -2 can cause lethal events [
32]. This latter, first emerging in China at the end of 2019 [
32], can lead to severe pneumonia and, being easily transmissible, has spread worldwide rapidly, leading the World Health Organization (WHO) to declare COVID-19 a pandemic [
33]. Currently, there are more than two million deaths (2,566,793, as found in Worldometers.info [
34] accessed on 3 March 2021) worldwide due to COVID-19, with enormous consequences for the public health and the economy worldwide [
35,
36,
37]. While the whole world is fighting against COVID19 and awaits an effective mass immunization, the scientific community is devoting immense efforts toward developing specific therapies for the treatment of SARS-CoV-2 infection. Moreover, since inflammatory cytokine storms together with immune system impairment are commonly observed in patients with severe COVID-19, several research studies have highlighted the advantages of dual therapies with antiviral and anti-inflammatory benefits [
38,
39]. Due to the urgent need for such a pharmacological treatment, drug repurposing [
40,
41,
42] and herbal medicine are two of the most considered anti-COVID-19 approaches [
43,
44,
45,
46,
47]. In fact, several plants such as mulberry, tea, and Dragon’s Blood tree are known as remedies to treat respiratory ailments and for their anti-inflammatory and antithrombotic properties, which are useful aspects in the fight against COVID-19 [
48,
49,
50,
51,
52].